249 related articles for article (PubMed ID: 14600095)
61. 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines.
Mitchell C; Park MA; Zhang G; Han SI; Harada H; Franklin RA; Yacoub A; Li PL; Hylemon PB; Grant S; Dent P
Mol Cancer Ther; 2007 Feb; 6(2):618-32. PubMed ID: 17308059
[TBL] [Abstract][Full Text] [Related]
62. 17AAG: low target binding affinity and potent cell activity--finding an explanation.
Chiosis G; Huezo H; Rosen N; Mimnaugh E; Whitesell L; Neckers L
Mol Cancer Ther; 2003 Feb; 2(2):123-9. PubMed ID: 12589029
[TBL] [Abstract][Full Text] [Related]
63. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
64. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
65. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
Cancer Res; 2003 Jun; 63(12):3241-6. PubMed ID: 12810654
[TBL] [Abstract][Full Text] [Related]
66. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A
Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799
[TBL] [Abstract][Full Text] [Related]
67. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
68. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.
Smith-Jones PM; Solit DB; Akhurst T; Afroze F; Rosen N; Larson SM
Nat Biotechnol; 2004 Jun; 22(6):701-6. PubMed ID: 15133471
[TBL] [Abstract][Full Text] [Related]
69. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.
Guo W; Reigan P; Siegel D; Ross D
Drug Metab Dispos; 2008 Oct; 36(10):2050-7. PubMed ID: 18635747
[TBL] [Abstract][Full Text] [Related]
70. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.
Villa R; Folini M; Porta CD; Valentini A; Pennati M; Daidone MG; Zaffaroni N
Carcinogenesis; 2003 May; 24(5):851-9. PubMed ID: 12771028
[TBL] [Abstract][Full Text] [Related]
71. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.
Nguyen DM; Chen A; Mixon A; Schrump DS
J Thorac Cardiovasc Surg; 1999 Nov; 118(5):908-15. PubMed ID: 10534697
[TBL] [Abstract][Full Text] [Related]
72. Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors.
Kang J; Kamal A; Burrows FJ; Evers BM; Chung DH
Anticancer Res; 2006; 26(3A):1903-8. PubMed ID: 16827123
[TBL] [Abstract][Full Text] [Related]
73. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
[TBL] [Abstract][Full Text] [Related]
74. Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.
Kim YM; Pyo H
DNA Cell Biol; 2012 Jan; 31(1):15-29. PubMed ID: 21830942
[TBL] [Abstract][Full Text] [Related]
75. Potent triazolothione inhibitor of heat-shock protein-90.
Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B
Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743
[TBL] [Abstract][Full Text] [Related]
76. [Influence of 17AAG on proliferation and invasion of gastric cancer cell and its mechanism].
Cui Y; Yu Y; Liu T; Xie Q; Wu W; Liu K
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Oct; 17(10):1031-5. PubMed ID: 25341914
[TBL] [Abstract][Full Text] [Related]
77. Altered Hsp90 function in cancer: a unique therapeutic opportunity.
Bagatell R; Whitesell L
Mol Cancer Ther; 2004 Aug; 3(8):1021-30. PubMed ID: 15299085
[TBL] [Abstract][Full Text] [Related]
78. Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.
Hackl C; Lang SA; Moser C; Mori A; Fichtner-Feigl S; Hellerbrand C; Dietmeier W; Schlitt HJ; Geissler EK; Stoeltzing O
BMC Cancer; 2010 Dec; 10():668. PubMed ID: 21129190
[TBL] [Abstract][Full Text] [Related]
79. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
80. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
Eiseman JL; Lan J; Lagattuta TF; Hamburger DR; Joseph E; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2005 Jan; 55(1):21-32. PubMed ID: 15338192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
